Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 472

1.

A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.

Park JS, Hong MH, Chun YJ, Kim HR, Cho BC.

Lung Cancer. 2019 Aug;134:46-51. doi: 10.1016/j.lungcan.2019.05.030. Epub 2019 May 28.

PMID:
31319994
2.

Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors.

Kim G, Yoo M, Hong MH, Lee BW, Kang ES, Cha BS, Kim HR, Lee YH, Cho BC.

Cancer Chemother Pharmacol. 2019 Aug;84(2):405-414. doi: 10.1007/s00280-019-03889-0. Epub 2019 Jun 27.

PMID:
31250153
3.

In Response.

Grant MC, Lester L, Cho BC.

Anesth Analg. 2019 Jun 17. doi: 10.1213/ANE.0000000000004297. [Epub ahead of print] No abstract available.

PMID:
31219922
4.

How do I audit intraoperative blood component utilization in cardiac surgery?

Hensley NB, Cho BC, Visagie M, Lester LC, Abernathy JH 3rd, Frank SM.

Transfusion. 2019 Jun 14. doi: 10.1111/trf.15399. [Epub ahead of print]

PMID:
31198989
5.

A Prospective Study of Magnetic Resonance Imaging Assessment of Post-radiation Changes Following Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer.

Munoz-Schuffenegger P, Kandel S, Alibhai Z, Hope A, Bezjak A, Sun A, Simeonov A, Cho BCJ, Giuliani M.

Clin Oncol (R Coll Radiol). 2019 Jun 5. pii: S0936-6555(19)30206-7. doi: 10.1016/j.clon.2019.05.014. [Epub ahead of print]

PMID:
31176537
7.

The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Gomez DR, Rimner A, Simone CB 2nd, Cho BCJ, de Perrot M, Adjei AA, Bueno R, Gill RR, Harpole DH Jr, Hesdorffer M, Hirsch FR, Jackson AA, Pass HI, Rice DC, Rusch VW, Tsao AS, Yorke E, Rosenzweig K.

J Thorac Oncol. 2019 Jul;14(7):1172-1183. doi: 10.1016/j.jtho.2019.03.030. Epub 2019 May 22. Review.

PMID:
31125736
8.

Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer.

Hong MH, Kim HR, Ahn BC, Heo SJ, Kim JH, Cho BC.

Yonsei Med J. 2019 Jun;60(6):525-534. doi: 10.3349/ymj.2019.60.6.525.

9.

On-label compared to off-label four-factor prothrombin complex concentrate use: a retrospective, observational study.

Cho BC, Jung YH, DeMario VM, Lau E, Podlasek SJ, Grant MC, Gehrie EA, Frank SM.

Transfusion. 2019 May 23. doi: 10.1111/trf.15355. [Epub ahead of print]

PMID:
31121073
10.

Usefulness of the LigaSure™ small jaw sealing device for breast reconstruction with a latissimus dorsi flap.

Lee JS, Kim DG, Lee JW, Choi KY, Chung HY, Cho BC, Yang JD.

J Plast Surg Hand Surg. 2019 May 7:1-6. doi: 10.1080/2000656X.2019.1612753. [Epub ahead of print]

PMID:
31062994
11.

Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma.

Lim SM, Choi JW, Hong MH, Jung D, Lee CY, Park SY, Shim HS, Sheen S, Kwak KI, Kang DR, Cho BC, Kim HR.

Lung Cancer. 2019 May;131:139-146. doi: 10.1016/j.lungcan.2019.04.002. Epub 2019 Apr 3.

PMID:
31027691
12.

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.

Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, Kim Y, Choi SJ, Yoon HI, Lee JG, Lee CY, Park SY, Park SH, Cho BC, Shim HS, Shin EC, Kim HR.

Ann Oncol. 2019 Apr 12. pii: mdz123. doi: 10.1093/annonc/mdz123. [Epub ahead of print]

PMID:
30977778
13.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA.

Oncologist. 2019 Apr 11. pii: theoncologist.2018-0695. doi: 10.1634/theoncologist.2018-0695. [Epub ahead of print]

PMID:
30975923
14.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators.

Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.

PMID:
30955977
15.

Application of Cultured Epidermal Homograft (Kaloderm) for Wide Scar Treatment.

Lee JS, Chu SG, Lee JW, Choi KY, Yang JD, Cho BC, Jeon S, Chung HY.

J Craniofac Surg. 2019 Mar 27. doi: 10.1097/SCS.0000000000005485. [Epub ahead of print]

PMID:
30939560
16.

Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors.

Lee HW, Choi B, Kang HN, Kim H, Min A, Cha M, Ryu JY, Park S, Sohn J, Shin K, Yun MR, Han JY, Shon MJ, Jeong C, Chung J, Lee SH, Im SA, Cho BC, Yoon TY.

Nat Biomed Eng. 2018 Apr;2(4):239-253. doi: 10.1038/s41551-018-0212-3. Epub 2018 Apr 2.

PMID:
30936439
17.

Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate.

Suh JW, Park SY, Lee CY, Song SH, Kim DJ, Paik HC, Chung KY, Hong MH, Kim HR, Cho BC, Lee JG.

PLoS One. 2019 Mar 26;14(3):e0214291. doi: 10.1371/journal.pone.0214291. eCollection 2019.

18.

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.

Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, Park SY, Yoon HI, Hong MH, Cho BC, Kim HR.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1613-1623. doi: 10.1007/s00432-019-02899-y. Epub 2019 Mar 25.

19.

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.

J Thorac Oncol. 2019 Jul;14(7):1233-1243. doi: 10.1016/j.jtho.2019.03.007. Epub 2019 Mar 20.

20.

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

Cho BC, Obermannova R, Bearz A, McKeage M, Kim DW, Batra U, Borra G, Orlov S, Kim SW, Geater SL, Postmus PE, Laurie SA, Park K, Yang CT, Ardizzoni A, Bettini AC, de Castro G Jr, Kiertsman F, Chen Z, Lau YY, Viraswami-Appanna K, Passos VQ, Dziadziuszko R.

J Thorac Oncol. 2019 Jul;14(7):1255-1265. doi: 10.1016/j.jtho.2019.03.002. Epub 2019 Mar 7.

21.

Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study.

Cho BC, DE Pas T, Kalofonos H, Wang Q, Ramlau R, Cheng Y, Vitiello F, Laisaar T, Vallières E, Kubisa B, Orlov S, Park K, Debruyne C, Vansteenkiste J.

Anticancer Res. 2019 Mar;39(3):1403-1409. doi: 10.21873/anticanres.13255.

PMID:
30842175
22.

Hemostatic properties of cold-stored whole blood leukoreduced using a platelet-sparing versus a non-platelet-sparing filter.

Haddaway K, Bloch EM, Tobian AAR, Frank SM, Sikorski R, Cho BC, Zheng G, Jani J, Lokhandwala PM, Lawrence CE, Blagg L, Ness PM, Kickler TS, Gehrie EA.

Transfusion. 2019 May;59(5):1809-1817. doi: 10.1111/trf.15159. Epub 2019 Feb 11.

PMID:
30741432
23.

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.

Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, Sun JM, Cho BC, Özgüroğlu M, Kojima T, Kostorov V, Hierro C, Zhu Y, McLean LA, Shah S, Doi T.

Future Oncol. 2019 Apr;15(10):1057-1066. doi: 10.2217/fon-2018-0609. Epub 2019 Feb 8.

24.

Comparisons among four types of absorbable plates used for internal fixation of zygomaticomaxillary complex fractures.

Chu SG, Lee JS, Lee JW, Yang JD, Chung HY, Cho BC, Choi KY.

J Craniomaxillofac Surg. 2019 Mar;47(3):383-388. doi: 10.1016/j.jcms.2019.01.014. Epub 2019 Jan 17.

PMID:
30711471
25.

Successful Ascending Aorta and Hemiarch Replacement and Aortic Valve Resuspension Via Redo Median Sternotomy Using Hypothermic Circulatory Arrest in a Practicing Jehovah's Witnesses Patient.

Gamble JF, Maxwell CD, Gaca J, Guinn NR, Cho BC, Frank SM, Tibi PR.

J Cardiothorac Vasc Anesth. 2019 May;33(5):1447-1454. doi: 10.1053/j.jvca.2018.12.019. Epub 2018 Dec 21. No abstract available.

PMID:
30704828
26.

Surgical correction for Tessier number 7 craniofacial cleft using a medially overcorrected design.

Ryu JY, Eo PS, Tian L, Lee JS, Lee JW, Choi KY, Yang JD, Chung HY, Cho BC.

Arch Plast Surg. 2019 Jan;46(1):16-22. doi: 10.5999/aps.2018.01193. Epub 2019 Jan 15.

27.

YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.

Yun J, Hong MH, Kim SY, Park CW, Kim S, Yun MR, Kang HN, Pyo KH, Lee SS, Koh JS, Song HJ, Kim DK, Lee YS, Oh SW, Choi S, Kim HR, Cho BC.

Clin Cancer Res. 2019 Apr 15;25(8):2575-2587. doi: 10.1158/1078-0432.CCR-18-2906. Epub 2019 Jan 22.

PMID:
30670498
28.

Impact of Preoperative Erythropoietin on Allogeneic Blood Transfusions in Surgical Patients: Results From a Systematic Review and Meta-analysis.

Cho BC, Serini J, Zorrilla-Vaca A, Scott MJ, Gehrie EA, Frank SM, Grant MC.

Anesth Analg. 2019 May;128(5):981-992. doi: 10.1213/ANE.0000000000004005.

PMID:
30649068
29.

Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.

Pyo KH, Kim JH, Lee JM, Kim SE, Cho JS, Lim SM, Cho BC.

Lung Cancer. 2019 Jan;127:112-121. doi: 10.1016/j.lungcan.2018.11.035. Epub 2018 Nov 27.

PMID:
30642538
30.

Impact of traffic volumes on levels, patterns, and toxicity of polycyclic aromatic hydrocarbons in roadside soils.

Kim SJ, Park MK, Lee SE, Go HJ, Cho BC, Lee YS, Choi SD.

Environ Sci Process Impacts. 2019 Jan 23;21(1):174-182. doi: 10.1039/c8em00532j.

PMID:
30632598
31.

A giant trichoblastic carcinoma.

Lee JS, Kwon JH, Jung GS, Lee JW, Yang JD, Chung HY, Cho BC, Choi KY.

Arch Craniofac Surg. 2018 Dec;19(4):275-278. doi: 10.7181/acfs.2018.02124. Epub 2018 Dec 27.

32.

A Safer Non-surgical Filler Augmentation Rhinoplasty Based on the Anatomy of the Nose.

Jung GS, Chu SG, Lee JW, Chung HY, Yang JD, Cho BC, Oh JW, Choi KY.

Aesthetic Plast Surg. 2019 Apr;43(2):447-452. doi: 10.1007/s00266-018-1279-7. Epub 2018 Dec 17.

PMID:
30560283
33.

Safe delayed procedure of nipple reconstruction in poorly circulated nipple.

Lee JS, Eom JR, Lee JW, Choi KY, Chung HY, Cho BC, Yang JD.

Breast J. 2019 Jan;25(1):129-133. doi: 10.1111/tbj.13167. Epub 2018 Dec 17.

PMID:
30557907
34.

Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity.

Ryu HJ, Kim EK, Cho BC, Yoon SO.

Head Neck. 2019 Jan;41(1):198-207. doi: 10.1002/hed.25507. Epub 2018 Dec 10.

PMID:
30536665
35.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ.

Cancer Discov. 2019 Mar;9(3):384-395. doi: 10.1158/2159-8290.CD-18-0839. Epub 2018 Nov 28.

PMID:
30487236
36.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY.

Ann Oncol. 2019 Jan 1;30(1):19-33. doi: 10.1093/annonc/mdy502.

PMID:
30475956
37.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY.

Ann Oncol. 2019 Jan 1;30(1):34-43. doi: 10.1093/annonc/mdy498.

PMID:
30475943
38.

Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.

Kim EK, Kim KA, Lee CY, Kim S, Chang S, Cho BC, Shim HS.

Clin Lung Cancer. 2019 Jan;20(1):e123-e132. doi: 10.1016/j.cllc.2018.10.004. Epub 2018 Oct 11.

PMID:
30391211
39.

Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus Infection.

Cho YA, Chung JM, Ryu H, Kim EK, Cho BC, Yoon SO.

Cancer Res Treat. 2019 Jul;51(3):1052-1063. doi: 10.4143/crt.2018.411. Epub 2018 Oct 24.

40.

A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.

Lee SY, Kim MH, Jang M, Park Y, Cho BC.

Eur J Cancer. 2018 Nov;104:104-107. doi: 10.1016/j.ejca.2018.09.015. Epub 2018 Oct 18. No abstract available.

PMID:
30342309
41.

The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer.

Kim HR, Park SM, Seo SU, Jung I, Yoon HI, Gabrilovich DI, Cho BC, Seong SY, Ha SJ, Youn JI.

Am J Respir Crit Care Med. 2019 Jan 15;199(2):243-246. doi: 10.1164/rccm.201808-1502LE. No abstract available.

PMID:
30339766
42.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.

PMID:
30280658
43.

Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.

Kang HN, Choi JW, Shim HS, Kim J, Kim DJ, Lee CY, Hong MH, Park SY, Park AY, Shin EJ, Lee SY, Pyo KH, Yun MR, Choi HM, Lee SS, Kim SY, Lee H, Paik S, Cho BC, Lee JG, Kim HR.

Lung Cancer. 2018 Oct;124:168-178. doi: 10.1016/j.lungcan.2018.08.008. Epub 2018 Aug 11.

PMID:
30268457
44.

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.

Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y.

J Thorac Oncol. 2019 Jan;14(1):99-106. doi: 10.1016/j.jtho.2018.09.004. Epub 2018 Sep 18.

PMID:
30240852
45.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J.

J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. [Epub ahead of print]

PMID:
30153097
46.

Complete genome of streamlined marine actinobacterium Pontimonas salivibrio strain CL-TW6T adapted to coastal planktonic lifestyle.

Cho BC, Hardies SC, Jang GI, Hwang CY.

BMC Genomics. 2018 Aug 22;19(1):625. doi: 10.1186/s12864-018-5019-9.

47.

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT.

Cancer Discov. 2018 Oct;8(10):1227-1236. doi: 10.1158/2159-8290.CD-18-0484. Epub 2018 Aug 9.

PMID:
30093503
48.

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.

Cho BC, Dy GK, Govindan R, Kim DW, Pennell NA, Zalcman G, Besse B, Kim JH, Koca G, Rajagopalan P, Langer S, Ocker M, Nogai H, Barlesi F.

Lung Cancer. 2018 Sep;123:14-21. doi: 10.1016/j.lungcan.2018.04.022. Epub 2018 Apr 27.

49.

Discharge Hemoglobin Level and 30-Day Readmission Rates After Coronary Artery Bypass Surgery.

Cho BC, DeMario VM, Grant MC, Hensley NB, Brown CH 4th, Hebbar S, Mandal K, Whitman GJ, Frank SM.

Anesth Analg. 2019 Feb;128(2):342-348. doi: 10.1213/ANE.0000000000003671.

PMID:
30059402
50.

Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.

Lee JS, Lee KH, Cho EK, Kim DW, Kim SW, Kim JH, Cho BC, Kang JH, Han JY, Min YJ, Park K.

Lung Cancer. 2018 Aug;122:234-242. doi: 10.1016/j.lungcan.2018.05.023. Epub 2018 May 24.

Supplemental Content

Loading ...
Support Center